Mochi Health and Mounjaro: Tirzepatide Program Explained

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This PlexusDx Education Hub article clarifies what Mounjaro is and how a GLP-1 telehealth program approaches tirzepatide. Browse all Peptides & GLP-1 education

Independent editorial note: PlexusDx operates a competing weight-management program and has no affiliate link, partnership, or commercial relationship with Mochi Health or the makers of Mounjaro.

Mounjaro is a brand name for tirzepatide, and searches pairing it with a telehealth program usually reflect one question: can I get tirzepatide here, and in what form? This editorial explains what Mounjaro actually is, how a program like Mochi Health tends to handle tirzepatide, the difference between branded and compounded versions, and the biology underneath the choice. Fair-balance framing, current as of April 2026.

What Mounjaro actually is

Mounjaro is the brand name under which tirzepatide is marketed as an FDA-approved product. Tirzepatide is a GIP/GLP-1 dual agonist, meaning it engages two incretin pathways rather than one. That dual mechanism is what distinguishes it from single-target GLP-1 receptor agonists, and it is the same active compound whether encountered as a brand product or in a compounded formulation.

How a program like Mochi Health handles tirzepatide

Mochi Health (Mochi Health) operates as telehealth with insurance support. In this model a licensed clinician reviews your intake and, when eligibility is met, routes a prescription either to a retail pharmacy for an FDA-approved brand product or to a 503A compounding pharmacy for compounded tirzepatide. Which route applies depends on the program and your circumstances; the specifics are documented at Mochi Health's official website.

Branded Mounjaro versus compounded tirzepatide

Branded Mounjaro is an FDA-approved product dispensed by a retail pharmacy. Compounded tirzepatide is prepared by a 503A compounding pharmacy against an individual prescription. Both deliver the same active compound, but they differ in regulatory status, availability, and cost, and telehealth programs vary in which they offer. Understanding which one a program dispenses is central to knowing what you are actually receiving.

The tirzepatide evidence base

Tirzepatide's clinical record centers on the SURMOUNT program for weight management (The New England Journal of Medicine, 2022) and SURMOUNT-OSA for obstructive sleep apnea (NEJM 2024). For context within the broader class, semaglutide was studied in STEP (NEJM 2021). Trial populations and endpoints differ across these programs, and individual outcomes vary regardless of whether the tirzepatide is branded or compounded.

The genetic layer beneath any tirzepatide decision

Because tirzepatide engages incretin biology, your own metabolic genetics shape the terrain it acts on. Variants in GLP1R (the GLP-1 receptor arm of tirzepatide's dual mechanism), FTO (the fat-mass and obesity-associated gene), MC4R (central to satiety), and TCF7L2 (linked to glucose homeostasis and incretin secretion) map your baseline. They are pathway-level markers — they do not predict response to tirzepatide or any specific compound, but they describe the biology into which it is prescribed.

PlexusDx offers tirzepatide through its Weight Management Protocols, available as Tirzepatide Injection and Tirzepatide Oral, alongside its semaglutide options. The Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights, including the variants above. For more, see GLP 1 Receptor Agonist and GLP 1 Drugs.

Not affiliated: PlexusDx has no commercial relationship with Mochi Health or with the manufacturer of Mounjaro.

Disclaimer: This article is educational. PlexusDx is not affiliated with Mochi Health or the makers of Mounjaro. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols, so this review compares approaches within the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Explore tirzepatide with genetic context: view the Weight Management Protocols, or start with the Precision Peptide Genetic Test.

Frequently Asked Questions About Mochi Health and Mounjaro

Is Mounjaro the same as tirzepatide?

Mounjaro is a brand name for tirzepatide, a GIP/GLP-1 dual agonist. The active compound is identical whether encountered as branded Mounjaro from a retail pharmacy or as compounded tirzepatide from a 503A pharmacy. The differences lie in regulatory status, availability, and cost rather than the molecule itself.

Does Mochi Health prescribe branded Mounjaro or compounded tirzepatide?

That depends on the program and your circumstances. A telehealth service may route a prescription to a retail pharmacy for an FDA-approved brand product or to a 503A compounding pharmacy for a compounded formulation. Confirm which pathway applies on the brand's own website before enrolling.

What does the tirzepatide research show?

The SURMOUNT program (NEJM 2022) studied tirzepatide for weight management, and SURMOUNT-OSA (NEJM 2024) examined it for obstructive sleep apnea. Trial populations and endpoints differ, and individual outcomes vary. The evidence describes the compound class, not what any single person will experience on a given protocol.

Can genetics tell me if tirzepatide will work for me?

No. The Precision Peptide Genetic Test does not predict response to tirzepatide or Mounjaro. It maps pathway-level variants such as GLP1R and FTO that shape your baseline metabolic biology, giving you and your provider context for the conversation rather than a forecast of any medication's effect.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.